Attention Deficit Hyperactivity Disorder Clinical Trial
— PADA1Official title:
Development of a Virtual Reality Application for the Diagnosis of Childhood ADHD: an Exploratory Study
NCT number | NCT04561713 |
Other study ID # | 2018/33 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 21, 2020 |
Est. completion date | March 21, 2023 |
The aim of this study is to develop an application in order to identify the most relevant cognitive and behavioral parameters for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in conditions closer to reality
Status | Recruiting |
Enrollment | 42 |
Est. completion date | March 21, 2023 |
Est. primary completion date | March 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 12 Years |
Eligibility | Inclusion Criteria: Group of children with ADHD : - Children aged 8 to 12 diagnosed with ADHD (according to DSM-V criteria) - Positive ADHD diagnosis with standardized maintenance of Kiddie-Sads - Naïve drug treatment for ADHD - Schooled in a classic environment - Intellectual Quotient> 80 (4 subtests of WASI, or WISC IV-R / WISC-V less than 2 years old) - Having French as mother tongue - Children benefiting from a social security scheme - Signing of free, informed and written consent by the child and the holders of parental authority Group of children controls Children aged 8 to 12 years undiagnosed ADHD (according to DSM-V criteria) : - Not presenting with ADHD at standardized maintenance Kiddie-Sads - Schooled in a classic environment - Intellectual Quotient> 80 (4 subtests of WASI) - Having French as mother tongue - Children benefiting from a social security scheme - Signing of free, informed and written consent by the child and the holders of parental authority Exclusion Criteria: - Positive diagnosis with standardized maintenance of Kiddie-Sads for the following disorders: mood disorders, psychotic disorders, autism spectrum disorders, severe anxiety disorders and severe tic disorders - Presenting a hearing or vision diagnosis diagnosed that does not allow the task to be performed in virtual reality - Neurological disorders - Photosensitive Epilepsy (contraindication to immersion in virtual reality) - Treatment with psychostimulants or other psychotropic drugs - Unable to complete the virtual reality task during the familiarization session |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average number of commission errors | Average number of commission errors to the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Average reaction time (ms) | The average reaction time (ms) to the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Average number of omission errors | Average number of omission errors to the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Average number of head movement | The average amount of head movement to the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Average number of foot movement | The average amount of foot movement to the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Percentage | The percentage of periods with emotions during the virtual reality task | From one day to 8 weeks after day 0 | |
Secondary | Percentage of period with presence of Emotion | Percentage of period with presence of Emotion (Engagement > 50) during the task of virtual reality (range from 0 to 100). | From one day to 8 weeks after day 0 | |
Secondary | Mean Emotion intensity (Engagement) | Mean Emotion intensity (Engagement) during the task of virtual reality (range from 0 to 100). | From one day to 8 weeks after day 0 | |
Secondary | Mean Emotion valence | Mean Emotion valence (negative or positive emotion) during the task of virtual reality (range from -100 to 100). | From one day to 8 weeks after day 0 | |
Secondary | Average reaction time (ms) | The average reaction time (ms) to the Continuous Performance Test (CPT) wich is a neuropsychological assessment test of sustained attention | Day 0 | |
Secondary | Average number of commission errors | The average number of commission errors to the CPT neuropsychological task | Day 0 | |
Secondary | Average number of omission errors | The average number of omission errors to the CPT neuropsychological task | Day 0 | |
Secondary | Total score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. | Scale to assess the severity of the 18 symptoms of DSM related to ADHD, the higher score mean a worse outcome. Max value : 54 | Day 0 | |
Secondary | Inattention score with the Attention-Deficit Hyperactivity Disorder-Rating Scale | Inattention score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. With inattention (items impairs) max value = 27, the higher score mean a worse outcome | Day 0 | |
Secondary | Hyperactivity score with the Attention-Deficit Hyperactivity Disorder-Rating Scale | Hyperactivity score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. Hyperactivity (items pairs) max value=27, the higher score mean a worse outcome | Day 0 | |
Secondary | Executive Performance Inventory Score | Executive Performance Inventory Score with Behavior Rating Inventory of Executive Function (BRIEF) questionnaire. Min value=30 and max value=100 the higher score mean a worse outcome. | Day 0 | |
Secondary | Quality of life (VSPA-e) score | Quality of life score with VSPA-e questionnaire. Min value= 0 and max value=100 the higher score mean a worse outcome | Day 0 | |
Secondary | Quality of life (KIDSCREEN) score | Quality of life with KIDSCREEN questionnaire. Min value= 0 and max value=100 the higher score mean a better outcome. | Day 0 | |
Secondary | Acceptability score of virtual reality tool | Acceptability score of virtual reality tool. Min value= 6 and max value=30 the higher score mean a better outcome. | From one day to 8 weeks after day 0 | |
Secondary | Acceptability score of classic neuropsychological test | Acceptability score of classic neuropsychological test. Min value= 6 and max value=30 the higher score mean a better outcome. | From one day to 8 weeks after day 0 | |
Secondary | Simulator Sickness score | Score on the "Simulator Sickness" questionnaire. Min value= 0 and max value=63 the higher score mean a worse outcome. | From one day to 8 weeks after day 0 | |
Secondary | Feeling of presence score | Score at the "feeling of presence" scale. Min value= -42 and max value=+42 The higher score mean a better immersion. | From one day to 8 weeks after day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06129396 -
Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT04779333 -
Lifestyle Enhancement for ADHD Program 2
|
N/A | |
Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
Completed |
NCT03148782 -
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
|
N/A | |
Completed |
NCT04832737 -
Strength-based Treatment Approach for Adults With ADHD
|
N/A | |
Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
Recruiting |
NCT05048043 -
Development of a Game-supported Intervention
|
N/A | |
Completed |
NCT03337646 -
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
|
Phase 4 | |
Not yet recruiting |
NCT06406309 -
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD
|
N/A | |
Not yet recruiting |
NCT06080373 -
Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial
|
N/A | |
Not yet recruiting |
NCT06454604 -
Virtual Reality Treatment for Emerging Adults With ADHD
|
Phase 2 | |
Completed |
NCT02477280 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance
|
Phase 4 | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT02473185 -
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest
|
Phase 4 | |
Completed |
NCT02829970 -
Helping College Students With ADHD Lead Healthier Lifestyles
|
N/A | |
Completed |
NCT02780102 -
Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD
|
N/A | |
Completed |
NCT02390791 -
New Technologies to Help Manage ADHD
|
N/A | |
Completed |
NCT02555150 -
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
|
Phase 3 | |
Recruiting |
NCT04175028 -
Neuromodulation of Executive Function in the ADHD Brain
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A |